FOLH1 and triple-negative breast carcinoma: Interestingly, the detection of prostate-specific membrane antigen (PSMA)-positive CTCs in patients with non-metastatic triple-negative breast cancer before and after neoadjuvant chemotherapy has shown clinical significance in identifying patients at a high risk for relapse [161].